The universal therapeutic agents of IBD, which aggressively target the characteristic inflammation, include 5-aminosalicylates (5-ASA), mesalazine, immunosuppressants, and biologics such as anti-TNF [11, 12]. This evidence concerns the gene TNF and inflammatory bowel disease.